To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

NCT07028320 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

493

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Osteoporosis

Interventions

DRUG: SAL056 (56.5μg)
DRUG: Alendronate

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.